<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35649245</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1752-8062</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical and translational science</Title><ISOAbbreviation>Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.</ArticleTitle><Pagination><StartPage>2010</StartPage><EndPage>2023</EndPage><MedlinePgn>2010-2023</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.13317</ELocationID><Abstract><AbstractText>RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to protect against cell death in a range of preclinical cellular and animal models of diseases. SAR443060 (previously DNL747) is a selective, orally bioavailable, central nervous system (CNS)-penetrant, small-molecule, reversible inhibitor of RIPK1. In three early-stage clinical trials in healthy subjects and patients with AD or ALS (NCT03757325 and NCT03757351), SAR443060 distributed into the cerebrospinal fluid (CSF) after oral administration and demonstrated robust peripheral target engagement as measured by a reduction in phosphorylation of RIPK1 at serine 166 (pRIPK1) in human peripheral blood mononuclear cells compared to baseline. RIPK1 inhibition was generally safe and well-tolerated in healthy volunteers and patients with AD or ALS. Taken together, the distribution into the CSF after oral administration, the peripheral proof-of-mechanism, and the safety profile of RIPK1 inhibition to date, suggest that therapeutic modulation of RIPK1 in the CNS is possible, conferring potential therapeutic promise for AD and ALS, as well as other neurodegenerative conditions. However, SAR443060 development was discontinued due to long-term nonclinical toxicology findings, although these nonclinical toxicology signals were not observed in the short duration dosing in any of the three early-stage clinical trials. The dose-limiting toxicities observed for SAR443060 preclinically have not been reported for other RIPK1-inhibitors, suggesting that these toxicities are compound-specific (related to SAR443060) rather than RIPK1 pathway-specific.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vissers</LastName><ForeName>Maurits F J M</ForeName><Initials>MFJM</Initials><Identifier Source="ORCID">0000-0001-7199-7301</Identifier><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuberger</LastName><ForeName>Jules A A C</ForeName><Initials>JAAC</Initials><Identifier Source="ORCID">0000-0001-7202-5088</Identifier><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groeneveld</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-4655-6667</Identifier><AffiliationInfo><Affiliation>Centre for Human Drug Research, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oude Nijhuis</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>Peter Paul</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadi</LastName><ForeName>Salah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PRA Health Sciences, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Herranz</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao-Nakamoto</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xinyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomponio</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Sanofi Genzyme, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Alonso</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanofi Genzyme, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zilberstein</LastName><ForeName>Moshe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanofi Genzyme, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sanofi Genzyme, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troyer</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03757325</AccessionNumber><AccessionNumber>NCT03757351</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Sci</MedlineTA><NlmUniqueID>101474067</NlmUniqueID><ISSNLinking>1752-8054</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506249">RIPK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053422" MajorTopicYN="Y">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.Ha., R.T., A.C.H., F.H., V.T., R.E., Y.Z., K.S.L., J.H.N., X.T., M.C., B.F., C.H., and M.T. are employees of and may hold stocks in Denali Therapeutics Inc. R.J.P., M.A.A., M.Z., and N.A. are employees of and may hold stocks in Sanofi (Genzyme). All other authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>16</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35649245</ArticleId><ArticleId IdType="pmc">PMC9372423</ArticleId><ArticleId IdType="doi">10.1111/cts.13317</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ting AT, Pimentel&#x2010;Mui&#xf1;os FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF&#x2010;&#x3ba;B but not Fas/APO&#x2010;1&#x2010;initiated apoptosis. EMBO J. 1996;15(22):6189&#x2010;6196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452440</ArticleId><ArticleId IdType="pubmed">8947041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14(11):727&#x2010;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">24129419</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313&#x2010;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="pubmed">18408713</ArticleId></ArticleIdList></Reference><Reference><Citation>Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81(5):1001&#x2010;1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951532</ArticleId><ArticleId IdType="pubmed">24508385</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar M, Suebsuwong C, Ray SS, et al. Structure guided design of potent and selective ponatinib&#x2010;based hybrid inhibitors for RIPK1. Cell Rep. 2015;10(11):1850&#x2010;1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494889</ArticleId><ArticleId IdType="pubmed">25801024</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Klausen C, Cheng JC, Leung PCK. CD40 ligand induces RIP1&#x2010;dependent, necroptosis&#x2010;like cell death in low&#x2010;grade serous but not serous borderline ovarian tumor cells. Cell Death Dis. 2015;6(8):e1864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558516</ArticleId><ArticleId IdType="pubmed">26313915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnoux A, Cluzeau C, Mitra S, et al. Necroptosis in niemann&#x2013;pick disease, type C1: a potential therapeutic target. Cell Death Dis. 2016;7(3):e2147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823930</ArticleId><ArticleId IdType="pubmed">26986514</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CCT, Davidson SM, Lim SY, Simpkin JC, Hothersall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21(4):227&#x2010;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17665295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukens JR, Vogel P, Johnson GR, et al. RIP1&#x2010;driven autoinflammation targets IL&#x2010;1&#x3b1; independently of inflammasomes and RIP3. Nature. 2013;498(7453):224&#x2010;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683390</ArticleId><ArticleId IdType="pubmed">23708968</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wu W, Li H, et al. Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice. J Spinal Cord Med. 2015;38(6):745&#x2010;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725808</ArticleId><ArticleId IdType="pubmed">24970278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10(11):1836&#x2010;1849. doi:10.1016/j.celrep.2015.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.02.051</ArticleId><ArticleId IdType="pmc">PMC4494996</ArticleId><ArticleId IdType="pubmed">25801023</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Wang H, Kang D, et al. Necrostatin&#x2010;1 ameliorates intracerebral hemorrhage&#x2010;induced brain injury in mice through inhibiting RIP1/RIP3 pathway. Neurochem Res. 2015;40(4):643&#x2010;650. doi:10.1007/s11064-014-1510-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-014-1510-0</ArticleId><ArticleId IdType="pubmed">25576092</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin B, Xu Y, Wei RL, He F, Luo BY, Wang JY. Inhibition of receptor&#x2010;interacting protein 3 upregulation and nuclear translocation involved in Necrostatin&#x2010;1 protection against hippocampal neuronal programmed necrosis induced by ischemia/reperfusion injury. Brain Res. 2015;1609(1):63&#x2010;71. doi:10.1016/j.brainres.2015.03.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.03.024</ArticleId><ArticleId IdType="pubmed">25801119</ArticleId></ArticleIdList></Reference><Reference><Citation>Viringipurampeer IA, Metcalfe AL, Bashar AE, et al. NLRP3 inflammasome activation drives bystander cone photoreceptor cell death in a P23H rhodopsin model of retinal degeneration. Hum Mol Genet. 2016;25(8):1501&#x2010;1516. doi:10.1093/hmg/ddw029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw029</ArticleId><ArticleId IdType="pmc">PMC4805309</ArticleId><ArticleId IdType="pubmed">27008885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Hu Z, Dufort C, et al. A RIPK1&#x2010;regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2021;118(13):e2025102118. doi:10.1073/PNAS.2025102118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2025102118</ArticleId><ArticleId IdType="pmc">PMC8020785</ArticleId><ArticleId IdType="pubmed">33766915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603&#x2010;608. doi:10.1126/science.aaf6803</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Branca C, Piras IS, et al. Necroptosis activation in Alzheimer's disease. Nat Neurosci. 2017;20(9):1236&#x2010;1246. doi:10.1038/nn.4608</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4608</ArticleId><ArticleId IdType="pubmed">28758999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Mazzitelli S, Ito Y, et al. RIPK1 mediates a disease&#x2010;associated microglial response in Alzheimer's disease. Proc Natl Acad Sci USA. 2017;114(41):E8788&#x2010;E8797. doi:10.1073/pnas.1714175114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1714175114</ArticleId><ArticleId IdType="pmc">PMC5642727</ArticleId><ArticleId IdType="pubmed">28904096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Ofengeim D, Yuan J. Receptor&#x2010;interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discovery. 2020;15:553&#x2010;571. doi:10.1038/s41573-020-0071-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0071-y</ArticleId><ArticleId IdType="pmc">PMC7362612</ArticleId><ArticleId IdType="pubmed">32669658</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelic M, Pontarelli F, Woodworth L, et al. RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis. Cell Rep. 2021;35(6):109112. doi:10.1016/j.celrep.2021.109112</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109112</ArticleId><ArticleId IdType="pmc">PMC8917516</ArticleId><ArticleId IdType="pubmed">33979622</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisel K, Berger S, Thorn K, et al. A randomized, placebo&#x2010;controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):1&#x2010;12. doi:10.1186/s13075-021-02468-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02468-0</ArticleId><ArticleId IdType="pmc">PMC7962407</ArticleId><ArticleId IdType="pubmed">33726834</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisel K, Scott NE, Tompson DJ, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol Res Perspect. 2017;5(6):e00365. doi:10.1002/prp2.365</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.365</ArticleId><ArticleId IdType="pmc">PMC5723699</ArticleId><ArticleId IdType="pubmed">29226626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1&#x2010;mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19&#x2010;33. doi:10.1038/s41583-018-0093-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0093-1</ArticleId><ArticleId IdType="pmc">PMC6342007</ArticleId><ArticleId IdType="pubmed">30467385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Ofengeim D, Yuan J. Receptor&#x2010;interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19(8):553&#x2010;571. doi:10.1038/s41573-020-0071-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0071-y</ArticleId><ArticleId IdType="pmc">PMC7362612</ArticleId><ArticleId IdType="pubmed">32669658</ArticleId></ArticleIdList></Reference><Reference><Citation>Grievink HW, Heuberger JAAC, Huang F, et al. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin Pharmacol Ther. 2020;107(2):406&#x2010;414. doi:10.1002/cpt.1615</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1615</ArticleId><ArticleId IdType="pubmed">31437302</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Swift B, Mamelok R, Pine S, Sinclair J, Attar M. Design and conduct considerations for first&#x2010;in&#x2010;human trials. Clin Transl Sci. 2019;12(1):6&#x2010;19. doi:10.1111/cts.12582</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12582</ArticleId><ArticleId IdType="pmc">PMC6342261</ArticleId><ArticleId IdType="pubmed">30048046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia. 2011;7(3):280&#x2010;292. doi:10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria &#x2013; 2015. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration. 2015;16(5&#x2013;6):291&#x2010;292. doi:10.3109/21678421.2015.1049183</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>
A study to evaluate the benefit and safety of GSK2982772 in moderate to severe psoriasis participants &#x2013; Full Text View &#x2013; ClinicalTrials.gov. Accessed May 22, 2021. https://clinicaltrials.gov/ct2/show/NCT04316585
</Citation></Reference><Reference><Citation>Vissers MFJM, Heuberger JAAC, Groeneveld GJ. Targeting for success: demonstrating proof&#x2010;of&#x2010;concept with mechanistic early phase clinical pharmacology studies for disease&#x2010;modification in neurodegenerative disorders. Int J Mol Sci. 2021;22(4):1&#x2010;33. doi:10.3390/ijms22041615</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041615</ArticleId><ArticleId IdType="pmc">PMC7915613</ArticleId><ArticleId IdType="pubmed">33562713</ArticleId></ArticleIdList></Reference><Reference><Citation>
Denali therapeutics announces positive clinical results and regulatory progress for development programs in Amyotrophic Lateral Sclerosis (ALS). Accessed Jan 20, 2022. https://www.globenewswire.com/en/news&#x2010;release/2021/10/06/2309876/0/en/Denali&#x2010;Therapeutics&#x2010;Announces&#x2010;Positive&#x2010;Clinical&#x2010;Results&#x2010;and&#x2010;Regulatory&#x2010;Progress&#x2010;for&#x2010;Development&#x2010;Programs&#x2010;in&#x2010;Amyotrophic&#x2010;Lateral&#x2010;Sclerosis&#x2010;ALS.html
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>